ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 822

Cigarette Smoking Is a Risk Factor for ANCA-Associated Vasculitis

Greg McDermott1, Xiaoqing Fu 1, John Stone 2, Yuqing Zhang 3, Hyon K. Choi 3 and Zachary Wallace 1, 1Massachusetts General Hospital, Boston, 2Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, 3Massachusetts General Hospital, Boston, MA

Meeting: ACR/ARP Annual Meeting 2019

Keywords: ANCA and vasculitis, tobacco use

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: 3S074: Epidemiology & Public Health I: Risk Factors & Outcomes for Rheumatic Diseases (821–826)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: ANCA-associated vasculitis (AAV) is a systemic small vessel vasculitis of unclear etiology associated with excess morbidity and mortality compared to the general population. Environmental exposures (e.g. asbestos) have been associated with AAV but the effect of cigarette smoking on disease risk is unclear. Previous studies suggest that smoking is associated with an increased risk of AAV relapse and its effect may vary according to age and disease manifestation. However, these findings were based on studies with relatively small sample size.  We performed a large case-control study to examine the association of cigarette smoking, a potentially modifiable factor, with the risk of AAV.

Methods: The Partners AAV (PAAV) Cohort is a consecutive inception cohort established at Partners HealthCare, a large hospital system in New England. All cases are PR3- or MPO-ANCA+.  Eosinophilic granulomatosis with polyangiitis cases were excluded.  For each AAV case, we randomly selected 3 controls from participants in the Partners HealthCare Biobank who completed a smoking questionnaire (N=30,536) and with no diagnosis of AAV and matched by sex, race, and age (± 2 years) at the index date (i.e., treatment initiation).  Smoking status at the index date was extracted from the electronic medical record and categorized into three groups: never, former, current. We examined the association between cigarette smoking and the odds of AAV using conditional logistic regression.  We performed stratified analyses to verify the robustness of the findings.

Results: We identified 473 AAV cases and 1,419 controls whose data on smoking status were available (mean age: 59 (±16) years; women: 59%, white: 84%). The majority (65%) of cases were MPO-ANCA+ and 64% had any baseline renal involvement. There was a greater proportion of current and former smokers among AAV cases (Current=43 [9%], Former=211 [45%]) than in the control group (Current=63 [4%], Former=533 [38%]). The multivariable adjusted odds ratios for AAV were 1.58 (95% CI:  1.25-2.00) for former cigarette smoking and 2.70 (95% CI 1.76-4.14) for current cigarette smoking as compared with non-smoking (Table 1).  When the proportion of ever-smokers was compared with that of never smokers, we found a similar association (1.72 [95% CI: 1.37-2.15]).  These associations persisted in stratified analyses by sex, ANCA type, and organ involvement though they did not reach statistical significance in the PR3-ANCA+ subgroup.  When we further matched cases and controls by education level, our findings were unchanged.  When we stratified by index date and whether or not a case had established care in Partners ≥ 1 year prior to the index date, our findings were unchanged.

Conclusion: In this large case-control study, being a current or former smoker was strongly associated with an increased risk of AAV, especially MPO-ANCA+ AAV. The precise biological mechanism underlying this association remains to be elucidated but may be related to cell apoptosis and necrosis, and/or oxidative endothelial stress. These findings suggest that cigarette smoking may be a modifiable risk factor for AAV. Additional studies are warranted to confirm these findings.

The Association of Cigarette Smoking with the Risk of ANCA-Associated Vasculitis


Disclosure: G. McDermott, None; X. Fu, None; J. Stone, Genentech, 2, 5, Roche, 2, 5, Xencor, 2, 5; Y. Zhang, None; H. Choi, AstraZeneca, 2, GSK, 5, Horizon, 5, Selecta, 5, Takeda, 5; Z. Wallace, National Institute of Arthritis, Musculoskeletal, and Skin Diseases, 2, Rheumatology Research Foundation, 2.

To cite this abstract in AMA style:

McDermott G, Fu X, Stone J, Zhang Y, Choi H, Wallace Z. Cigarette Smoking Is a Risk Factor for ANCA-Associated Vasculitis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/cigarette-smoking-is-a-risk-factor-for-anca-associated-vasculitis/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARP Annual Meeting 2019

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cigarette-smoking-is-a-risk-factor-for-anca-associated-vasculitis/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology